| On-line Adaptive Radiation Treatment of Prostate Cancer |
Jan-2009 |
22 pages |
| Authors:
Tiezhi Zhang; WILLIAM BEAUMONT HOSPITAL ROYAL OAK MI
|
 | The goal of this project is to develop an online adaptive treatment technique for prostate cancer treatments. During the first year, we have developed parallel deformable image registration, parallel dose calculation and plan optimization algorithms. During the second year, we have been focusing on improving the robustness of the algorithms and improving online image quality. |
|
| On-line Adaptive Radiation Treatment of Prostate Cancer |
Jan-2008 |
53 pages |
| Authors:
Tiezhi Zhang; WILLIAM BEAUMONT HOSPITAL ROYAL OAK MI
|
| Organ motion is a major uncertainty in prostate cancer treatment. In this project, we are developing online adaptive treatment that can compensate organ motion in daily treatments. The specific aims of this project are to develop the key technical components for online adaptive treatment, which include parallel deformable image registration algorithm, parallel dose calculation and plan optimization algorithms. |
|
| Pilot Study Testing the Technical Feasibility and Toxicity of High Dose Rate Brachytherapy Combined with Hyperthermia to Treat Prostate Cancer Recurrences after External Beam Irradiation or Permanent Seed Implant Failure |
JUL 2004 |
25 pages |
| Authors:
Peter M. Corry; Alvaro Martinez; WILLIAM BEAUMONT HOSPITAL ROYAL OAK MI
|
| The principal objective of this research is the development of the combination of hyperthermia (HT) and high dose rate (HDR) brachytherapy as a therapy for locally advanced, recurrent prostate cancer after failure using front line external beam definitive radiation therapy (EBRT). We had previously developed a system for low dose rate systems (LDR), however technological advances in HDR systems make the application of LDR essentially obsolete. There are several fundamentally ... |
|
| Thermobrachytherapy for Recurrent Prostate Cancer |
JUL 2003 |
13 pages |
| Authors:
Peter M. Corry; WILLIAM BEAUMONT HOSPITAL ROYAL OAK MI
|
| The principal objective of this research is the development of the combination of hyperthermia (HT) and high dose rate (HDR) brachytherapy as a therapy for locally advanced, recurrent prostate cancer after failure using front line external beam definitive radiation therapy (EBRT). We had previously developed a system for low dose rate systems (LDR), however technological advances in HDR systems make the application of LDR essentially obsolete. There are several fundamentally ... |
|
| Thermobrachytherapy for Recurrent Prostate Cancer |
JUL 2002 |
21 pages |
| Authors:
Peter M. Corry; Alvaro Martinez; WILLIAM BEAUMONT HOSPITAL ROYAL OAK MI
|
| The principal objective of this research is the development of the combination of hyperthermia (HT) and high dose rate (HDR) brachytherapy as a therapy for locally advanced, recurrent prostate cancer after failure using front line external beam definitive radiation therapy (EBRT). We had previously developed a system for low dose rate systems (LDR), however technological advances in HDR systems make the application of LDR essentially obsolete. There are several fundamentally ... |
|
| An On-Line Tomographic Guidance System for Dose Escalation in Radiotherapy for Adenocarcinoma of the Prostate |
AUG 2001 |
197 pages |
| Authors:
David A. Jaffray; WILLIAM BEAUMONT HOSPITAL ROYAL OAK MI
|
| There is strong evidence to support the hypothesis that increasing radiation dose to the prostate will increase the probability of cure. A major difficulty in pursuing dose escalation is the toxicity induced in the surrounding normal tissues. These normal tissues are irradiated as a consequence of planning margins used to guarantee the delivery of the prescribed dose to the entire clinical target volume (prostate and seminal vesicles). The margins are ... |
|
| Nitric Oxide Gene Therapy for Prostate Cancer |
APR 2001 |
25 pages |
| Authors:
Elwood P. Armour; WILLIAM BEAUMONT HOSPITAL ROYAL OAK MI
|
| Traditional therapies for advanced prostate cancer are unable to cure a majority of patients. An approach to therapy we have tested involves production of nitric oxide (NO) by introduction of replication defective adenovirus containing the DNA sequences for inducible nitric oxide synthase (INOS). An adenovirus vector with an iNOS cDNA and a CMV promoter (Ad5-CMV-iNOS) was constructed and tested. The production of nitric oxide in prostate cancer cells after infection ... |
|
| Nitric Oxide Gene Therapy for Prostate Cancer |
OCT 1999 |
22 pages |
| Authors:
Elwood Armour; WILLIAM BEAUMONT HOSPITAL ROYAL OAK MI
|
| Traditional therapies for advanced prostate cancer are unable to cure a majority of patients. One approach to therapy is over-production of inducible nitric oxide synthase (iNOS) within the tumor by injecting replication defective adenovirus containing the DNA sequences for iNOS into prostate tumors. The adenovims gene transfer technology is readily applicable and an iNOS, with CMV promoter, containing adenovirus (Ad5-CMV- iNOS) has been constructed and tested ... |
|
| Heat-Activated Gene Therapy |
SEP 1999 |
40 pages |
| Authors:
Michael J. Borrelli; WILLIAM BEAUMONT HOSPITAL ROYAL OAK MI
|
| The research goal is to develop heat shock as a modality for optimizing and controlling gene therapy for treating prostate cancer. Heat activatible tissue permeabilizers will increase dissemination of adenoviral vectors throughout solid tumors. The optimal permeabilizer has been identified and its usable ranges of concentration and activating heat shocks have been narrowed sufficiently to begin testing in human Xenograft tumors. A quantitative relationship between time at temperature and induced ... |
|
Reports by Corporate Author
